Renal Anemia | Access and Reimbursement | US | 2016
Renal Anemia | Access & Reimbursement | US examines the market access factors that influence the success of therapies for the treatment of renal anemia. The series is based on primary research data with U.S. nephrologists and MCO pharmacy and medical directors. This research explores how payers and physicians interact and how reimbursement decisions impact the prescribing and uptake of specific therapies at the brand level.
Related Market Assessment Reports
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is a prevalent complication of diabetes, typically causing persistent burning, tingling, or sharp pain in the extremities. Management relies on a range of…
Report
Bipolar Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Bipolar Disorder (US)
Bipolar disorder (BPD) is a chronic condition characterized by recurrent episodes of aberrant mood, with patients experiencing manic, depressive, or mixed symptoms between periods of stable mood…
Report
Rheumatoid Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Rheumatoid Arthritis (US)
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs) such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
